TITLE:
Effectiveness of KOS-862 in the Treatment of Lung Cancer

CONDITION:
Lung Cancer

INTERVENTION:
KOS-862

SUMMARY:

      The purpose of this study is to determine whether a potential drug known as KOS-862 or
      "Epothilone D" has an effect as a 2nd line treatment in non-small cell lung cancer (NSCLC)
      for patients having failed one prior platinum-containing chemotherapy regimen.
    

DETAILED DESCRIPTION:

      To determine the antitumor activity, based on the confirmed objective response rate, of
      KOS-862, administered intravenously weekly for 3 weeks every 4 weeks, in patients with
      non-small cell lung cancer (NSCLC) whose disease has progressed following initial
      chemotherapy for advanced or metastatic disease.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  At least 18 years of age

          -  Measurable disease

          -  One previous treatment of a platinum based drug such as cisplatin or carboplatin

          -  At least 3 weeks since last surgery/radiation/chemotherapy

        Exclusion Criteria:

          -  Brain metastases

          -  Changes in the rhythm of your heart that are considered significant as determined by
             an ECG tracing
      
